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Blood type gene locus has no influence on ACE association with Alzheimer's disease.
Anne Braae 1 , Christopher Medway 1 , Minerva Carrasquillo 2 , Steven Younkin 2 , Alzheimer's Research UK (ARUK) Consortium*, Patrick G Kehoe 3 and Kevin Morgan 1. Introduction The renin angiotensin system (RAS) has become a biological pathway of increasing interest in the pathogenesis of Alzheimer's disease (AD) and potentially as a basis for future interventions. Previous genetic associations between ACE, that encodes for angiotensin converting enzyme (ACE), one of the key enzymes in the RAS, played a significant role in the growing interest of this system in AD.
This was aided by the fact that the suggested ACE risk variant contributed to lower levels of plasma ACE while it was also shown that ACE degraded amyloid-β peptide, which is widely involved in the pathology of AD (reviewed in Kehoe and Wilcock, 2007) . However, more recent haplotype studies and Genome Wide Association Studies (GWAS) have not supported the role of ACE as a genetic risk factor for AD. Previous meta-analyses have suggested however the possibility that ACE may mediate risk via epistatic interactions with other genetic risk variants (Lehmann et al., 2005) .
Recently it was shown that the variants in the ABO blood group locus, independently and when combined with ACE variants, explained a greater proportion of the population variance of ACE in plasma than ACE alone (Terao et al., 2013) . In particular, alleles tagging the ABO blood group Type A1 were associated with the lowest plasma ACE activity, while alleles tagging Type B were associated with increased ACE activity and Type A2 and O alleles were associated with intermediate activity (Terao et al., 2013) . Given the previously suggested role of ACE activity in AD (Miners et al., 2008) we investigated whether variation in ABO when combined with ACE variation might be associated with increased risk of AD.
Methods
A combined GWAS dataset of 3448 samples from Alzheimer's Research UK (ARUK) and the Mayo Clinic genotyped on Illumina HumanHap300v1 was used. All samples were of European descent, 1487 males and 1922 females, 2069 cases with average age at death of 73.5 years (range 51-108) and 1379 controls with average age at death of 73.4 years (range 54-97 years), with APOE alleles: ε2 -5.7%; ε3 -65.9%; ε4 -28.4%. The power of the study to detect an association with AD was calculated in QUANTO v1.2.4.
The ABO and ACE regions were imputed against 1000 Genomes Phase I haplotypes in IMPUTE2.
Imputed data was further quality control checked resulting in 4599 SNPs in ACE for association testing. ABO blood group haplotypes were determined from the imputed ABO region and included as a covariate for the merged dataset. The imputed ACE region was association tested in PLINK (Purcell et al., 2007) using logistic regression corrected for sex, age at onset and APOE ε4 allele and including ABO type as an interaction term. The association test was also run including the blood group B allele and A1 allele separately as interaction terms. The power of the study to detect the interaction was calculated post-hoc using G*Power. For further details please see the supplementary materials.
Results
Power calculations in QUANTO v1.2.4 indicated 71% to 99% power at this sample size to detect an association with a genetic variant with MAF of 1% to 5% assuming a genetic odds ratio of 1.2 to 1.5.
ABO blood group haplotype was determined for 3396 samples, as the genotype was not available for all samples. The logistic regression model corrected for sex, age at onset and APOE ε4 allele dose and provided no evidence to support an ACE association with disease in this dataset (Suppl. Table 2, Suppl. Fig 1-3) .
Additionally, the interaction terms of ABO blood type and ACE variant and the interaction terms for the presence of a B allele or A1 allele and ACE variants were not significantly associated with disease status and failed to improve the model containing only covariates (Suppl. Fig 4,5) .
Post-hoc power analysis showed that the effective power was 77% to 83%.
Discussion
In this report we have determined if ABO blood type can potentially modify any association of ACE gene variation with AD. To address this issue we have used ABO haplotypes (both A1 and B alleles), modelling interactions reported for ABO with ACE on plasma ACE levels, to explore whether it had any additional effects on ACE SNP associations with AD (Suppl. Fig 1-5) . It should be noted that the majority of these cases were pathologically confirmed as AD so the contribution to vascular AD, which is biologically plausible, remains to be determined.
In summary, we find no evidence to support a role for ACE, modelled with ABO locus genotypes, being associated with the risk of developing AD.
